At present, the major indications approved for rituximab in China are follicular non-Hodgkin's lymphoma (NHL) and DLBCL.
Okwamanje, iziboniso ezisemqoka ezavunyelelwa i- rituximab eShayina ngumantshu wezimbotshana okungezona ze-Hodgkin (i-NHL) kanye ne-DLBCL.